BiotechTube

LGH447 + LGH447 + midostaurin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AML and High Risk MDS

Conditions

AML and High Risk MDS

Trial Timeline

Mar 20, 2014 → Apr 18, 2019

NCT ID
NCT02078609

About LGH447 + LGH447 + midostaurin

LGH447 + LGH447 + midostaurin is a phase 1 stage product being developed by Novartis for AML and High Risk MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT02078609. Target conditions include AML and High Risk MDS.

What happened to similar drugs?

6 of 20 similar drugs in AML and High Risk MDS were approved

Approved (6) Terminated (7) Active (9)
✅Bunazosin + Doxazosin + ValsartinEisaiApproved
✅AliskirenNovartisApproved
✅Aliskiren and HCTZNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
✅losartan potassium + Comparator: PlaceboOrganonApproved
❌Edoxaban + ASADaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02078609Phase 1Completed

Competing Products

20 competing products in AML and High Risk MDS

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Sepantronium BromideCothera BiosciencePhase 2
29
Edoxaban + ASADaiichi SankyoPhase 3
32
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
36
Bunazosin + Doxazosin + ValsartinEisaiApproved
43
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3
47
Camrelizumab、Rivoceranib + CamrelizumabJiangsu Hengrui MedicinePhase 2
35
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Mirvetuximab SoravtansineAbbViePhase 2
42
Zibotentan/Dapagliflozin + DapagliflozinAstraZenecaPhase 2
42
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tabletAstraZenecaPhase 1
29
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
40
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40